• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cytosorbents Cor (NQ: CTSO )

    0.8622 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Cytosorbents Cor

    < Previous 1 2 Next >
    CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification
    From CytoSorbents
    Via GlobeNewswire
    FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
    DrugSorb™-ATR is an FDA Breakthrough Device eligible for priority review with an FDA decision anticipated in 2025 
    From CytoSorbents
    Via GlobeNewswire
    CytoSorbents to Report Third Quarter 2024 Operating and Financial Results
    From CytoSorbents
    Via GlobeNewswire
    CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
    From CytoSorbents
    Via GlobeNewswire
    CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
    From CytoSorbents
    Via GlobeNewswire
    CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From CytoSorbents
    Via GlobeNewswire
    CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
    From CytoSorbents
    Via GlobeNewswire
    CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
    CytoSorbents CFO Kathleen P. Bloch Retires 
    From CytoSorbents
    Via GlobeNewswire
    CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
    From CytoSorbents
    Via GlobeNewswire
    CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement
    From CytoSorbents
    Via GlobeNewswire
    CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
    “Working to Save Lives Together” Theme Highlights Two Decades of Successful Collaboration with the International Medical and Research Communities to Help Patients Survive Life-Threatening Illnesses 
    From CytoSorbents
    Via GlobeNewswire
    CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress
    From CytoSorbents
    Via GlobeNewswire
    CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union
    By enabling more rapid and easy treatment, PuriFi is expected to increase the demand and sales of CytoSorbents’ leading CytoSorb® blood purification cartridge for critically ill patients in the... 
    From CytoSorbents
    Via GlobeNewswire
    CytoSorbents Secures $20 Million Credit Facility
    Credit facility provides timely non-dilutive capital to support ongoing global commercialization of CytoSorb® as well as regulatory submissions and potential commercialization plans for DrugSorb™-ATR... 
    From CytoSorbents
    Via GlobeNewswire
    CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting
    From CytoSorbents
    Via GlobeNewswire
    CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan
    Brings a powerful blood purification technology used to treat critically ill and cardiac surgery patients in nearly a quarter million treatments across 75 countries to date to one of the most... 
    From CytoSorbents
    Via GlobeNewswire
    CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract
    From CytoSorbents
    Via GlobeNewswire
    CytoSorbents Reports First Quarter 2024 Results
    From CytoSorbents
    Via GlobeNewswire
    CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
    From CytoSorbents
    Via GlobeNewswire
    CytoSorbents to Report First Quarter 2024 Operating and Financial Results
    From CytoSorbents
    Via GlobeNewswire
    STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
    From CytoSorbents
    Via GlobeNewswire
    CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
    From CytoSorbents
    Via GlobeNewswire
    CytoSorbents to Report Fiscal 2023 Operating and Financial Results
    From CytoSorbents
    Via GlobeNewswire
    CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
    From CytoSorbents
    Via GlobeNewswire
    Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
    CytoSorb Blood Purification Results in Statistically Significant Reductions in Multiple Organ Failure and Dysfunction 
    From CytoSorbents
    Via GlobeNewswire
    CYTOSORBENTS ALERT: Bragar Eagel & Squire, P.C. is Investigating Cytosorbents Corporation on Behalf of Cytosorbents Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
    From CytoSorbents
    Via GlobeNewswire
    CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
    Company insiders participated in the transaction with $435,000 of investment 
    From CytoSorbents
    Via GlobeNewswire
    CytoSorbents Reports Third Quarter 2023 Financial and Operational Results
    Q3 2023 Product sales grew 20% to $7.8M versus $6.5M in Q3 2022. Q3 2023 Total revenue was approximately $8.8M. The pivotal STAR-T trial remains blinded with database lock nearing and initial data... 
    From CytoSorbents
    Via GlobeNewswire
    CytoSorbents to Report Third Quarter 2023 Operating and Financial Results
    From CytoSorbents
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.